

Esther Oomen-de Hoop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8381055/publications.pdf>

Version: 2024-02-01

57
papers

1,017
citations

471061

17
h-index

525886

27
g-index

57
all docs

57
docs citations

57
times ranked

1735
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. <i>Radiotherapy and Oncology</i> , 2019, 140, 150-158.	0.3	67
2	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	1.3	65
3	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
4	Correlation between nivolumab exposure and treatment outcomes in non-“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	1.3	58
5	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	2.4	57
6	Hypofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 108-115.	0.4	43
7	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
8	High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. <i>Molecular Oncology</i> , 2019, 13, 392-402.	2.1	37
9	Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 3537-3545.	3.2	36
10	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. <i>Cancers</i> , 2019, 11, 403.	1.7	31
11	Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2019, 58, 74-80.	0.8	30
12	Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2018, 57, 1031-1037.	0.8	28
13	Locoregional control and survival after lymph node SBRT in oligometastatic disease. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 625-633.	1.7	28
14	Polymorphisms in <i>SLCO1B1</i> and <i>UGT1A1</i> are associated with sorafenib-induced toxicity. <i>Pharmacogenomics</i> , 2016, 17, 1483-1490.	0.6	26
15	Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 823-833.	0.4	22
16	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	1.7	21
17	Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 73-81.	0.4	21
18	Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 144, 23-29.	0.3	21

#	ARTICLE	IF	CITATIONS
19	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 48-54.	1.3	20
20	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. <i>Cancers</i> , 2018, 10, 134.	1.7	18
21	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	0.8	18
22	Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1456-1461.	2.3	17
23	Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2022, 61, 527-537.	1.6	17
24	Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. <i>Clinical Cancer Research</i> , 2018, 24, 541-546.	3.2	15
25	Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 107-113.	1.1	14
26	Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1304-1313.	2.3	14
27	The added value of H2 antagonists in premedication regimens during paclitaxel treatment. <i>British Journal of Cancer</i> , 2021, 124, 1647-1652.	2.9	14
28	Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 69-77.	1.6	12
29	Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study). <i>BMC Palliative Care</i> , 2018, 17, 105.	0.8	11
30	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3179.	1.7	11
31	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983896.	1.4	10
32	Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. <i>Cancers</i> , 2019, 11, 826.	1.7	9
33	Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 986-992.	1.1	9
34	Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT). <i>BMC Palliative Care</i> , 2019, 18, 106.	0.8	9
35	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. <i>Pharmaceutics</i> , 2020, 12, 788.	2.0	9
36	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. <i>Cancers</i> , 2021, 13, 1370.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634. <i>Cancers</i> , 2021, 13, 3741.	1.7	9
38	Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	8
39	The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 547-553.	1.1	8
40	The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. <i>Pharmaceutical Research</i> , 2020, 37, 7.	1.7	8
41	Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 119.	1.7	8
42	Effects of Implementation of a Standardized Palliative Care Pathway for Patients with Advanced Cancer in a Hospital: A Prospective Pre- and Postintervention Study. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 451-459.	0.6	7
43	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	1.3	7
44	Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 455-460.	2.3	6
45	Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. <i>Oncotarget</i> , 2018, 9, 18269-18276.	0.8	5
46	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. <i>Neuro-Oncology</i> , 2022, 24, 326-328.	0.6	5
47	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 759146.	1.6	5
48	Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. <i>PLoS ONE</i> , 2018, 13, e0198289.	1.1	3
49	Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy. <i>Acta Oncologica</i> , 2020, 59, 809-817.	0.8	3
50	Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy. <i>Cancers</i> , 2018, 10, 445.	1.7	2
51	Self-reported quality of life and hope in phase-I trial participants: An observational prospective cohort study. <i>European Journal of Cancer Care</i> , 2018, 27, e12908.	0.7	2
52	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. <i>Cancers</i> , 2021, 13, 3915.	1.7	2
53	Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210810.	1.4	2
54	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. <i>Cancers</i> , 2019, 11, 173.	1.7	1

#	ARTICLE	IF	CITATIONS
55	The moral and legal status of Health Care Workers in Cluster Randomized Trials: a response to Weijer and Taljaard. <i>Journal of Clinical Epidemiology</i> , 2019, 116, 146-149.	2.4	0
56	Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. <i>Genes</i> , 2020, 11, 358.	1.0	0
57	Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing. <i>Cancers</i> , 2022, 14, 1500.	1.7	0